Lilly Asia Ventures participated in a series A-plus-plus round pushing the genome editing technology developer's total funding past $100m.
China-based genome editing technology developer Qihan Biotechnology has secured $67m in a series A-plus-plus round featuring Lilly Asia Ventures, a strategic investment vehicle for pharmaceutical firm Eli Lilly.
The round included venture capital firms Matrix Partners China and Sequoia Capital China as well as CMB International, a subsidiary of financial services firm China Merchants Bank.
Qihan Bio is developing cell therapies and organs for transplants, using multiplexable genome editing technology. The cash will fund the development of its product pipeline…
